Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
Month
1
2
3
4
5
6
7
8
9
10
11
12
2023.05.16
Boan Biotech’s BA1202 Approved for Clinical Trial The First Novel CEA/CD3 Bispecific Antibody in China
2023.05.16
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China
2023.05.16
Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302
16
2023-05
Boan Biotech Signed A Strategic Cooperation Agreement with GenScript Biotech, Targeting the Field of Cell Therapy
11
2023-05
Boan Biotech Will Presents Results of Phase 3 Clinical Study for Denosumab Injection (BA1102) Conducted in China at the 2023 ASCO Annual Meeting
05
2023-05
First Subject Enrolled in Boan Biotech’s International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102
09
2023-05
Boan Biotech Releases Its First ESG Report, Shouldering ESG Responsibilities and Pursuing High-quality Development
13
2023-04
Boan to Remove “B” Marker from Its Stock Short Name at HKEX
11
2023-04
BLA for Boan's Boyounuo® (Bevacizumab) Accepted in Brazil
28
2023-03
Boan Biotech Announces 2022 Financial Results
1
2
3
4
5
Follow me
